The 15 drugs accounted for $27bn in spending via Medicare Part B and Part D between November 2024 and October 2025.
The US FDA has accepted for priority review Otsuka Pharmaceutical’s NDA submitted for centanafadine, an investigational, once-daily extended-release capsule for ADHD treatment.
Insilico Medicine has entered a strategic partnership with Qilu Pharmaceutical to develop treatments for cardiometabolic ...
This video explains the interactions within a protein cell network, what can go wrong, and how targeted drugs can alleviate these problems.
Other countries in Europe to lose eliminated status include Armenia, Austria, Azerbaijan, Spain, and Uzbekistan. Sustained ...
Eisai and Biogen have announced that the US FDA has accepted for review the sBLA submitted by the former for Leqembi Iqlik SC ...
The lack of initial public offerings (IPOs) also reflects a year of restricted growth. As per the BIA, no UK biotechs went ...
The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.
The UK's NICE now recommends the NHS use of Pfizer's daily prostate cancer pill, Talzenna alongside hormone therapy Xtandi.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results